ArticleFrontiers in oncology2026
Predictors of survival in triple-negative breast cancer patients treated with neoadjuvant chemotherapy, surgery, and radiotherapy.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Triple-negative breast cancer (TNBC) is known for its heterogeneity. Due to the small sample sizes in prior studies, there is limited understanding of whether different molecular subtypes have distinct predictive values following comprehensive treatment. Methods: Females with TNBC treated with neoadjuvant chemotherapy (NAC), surgery, and radiotherapy from 2019 to 2022 were retrospectively analyzed. Disease-free survival (DFS) and overall survival (OS) were evaluated using the Kaplan-Meier method to compare the basal-like immune-suppressed (BLIS) and non-BLIS subtypes. Univariate and multivariate Cox analyses were employed to identify prognostic factors for DFS. Results: The median follow-up time was 34 months. The 4-year DFS rates for non-BLIS and BLIS subtypes were 74.8% and 56.1%, respectively (P = .035). Independent predictors of DFS included molecular subtype (HR = 2.071, P = .034) and ypN status (HR for ypN1-2 = 4.891, P = .018; ypN3 = 7.444, P = .008). Additionally, both nodal stage and lymph node ratio categories (LNRC) were negatively correlated with DFS in both subgroups (P <.001 for both). Moreover, in the BLIS group, there was a statistically significant difference between low and high LNR (P < 0.05), while in the non-BLIS group, DFS differed significantly across subgroups with low, intermediate, or high LNRC (P < 0.05). Conclusions: Molecular subtyping plays a crucial role in prognosis, with the non-BLIS subtype showing more favorable outcomes. The presence of residual nodal disease post-NAC helps distinguish between favorable and unfavorable outcomes in different TNBC subtypes. These findings underscore the importance of developing more individualized radiotherapy strategies following NAC for each molecular subtype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.